chemical glycosylation synthesis glycoconjugate antitumour vaccines
therapeutic vaccines derived carbohydrate antigen adjuvant combinations promising approach cancer immunotherapy one critical limitations area access sufficient quantities tumour-associated carbohydrate antigens glycoconjugate adjuvants present availability complex oligosaccharide constructs needed systematic design evaluation novel vaccine formulations relies de novo chemical synthesis use state-of-the-art emerging glycosylation technologies led significant advances field allowing clinical exploration carbohydrate-based antigens treatment cancer
